Compare BLFY & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLFY | BNR |
|---|---|---|
| Founded | 1939 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.3M | 216.9M |
| IPO Year | N/A | 2020 |
| Metric | BLFY | BNR |
|---|---|---|
| Price | $13.07 | $35.26 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 483.7K | 34.1K |
| Earning Date | 01-21-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $44,731,000.00 | ★ $75,749,382.00 |
| Revenue This Year | $19.85 | $136.32 |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.52 | 5.56 |
| 52 Week Low | $7.61 | $2.18 |
| 52 Week High | $13.55 | $41.72 |
| Indicator | BLFY | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 65.54 |
| Support Level | $12.77 | $35.00 |
| Resistance Level | $13.55 | $41.72 |
| Average True Range (ATR) | 0.36 | 3.30 |
| MACD | -0.02 | 0.70 |
| Stochastic Oscillator | 69.65 | 72.87 |
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.